QURE | Ticker Profile - Titan Protect

QURE

uniQure N.V.

Healthcare · Biotechnology · NMS

$26.45

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.88

Based on estimated future earnings — lower means cheaper

Rev Growth

+127.3%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-228.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.07

+33% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

https://www.uniqure.com

Country: Netherlands Employees: 221 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.046

Excellent risk-adjusted returns

Kelly Fraction

0.1405

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.518

Returns exceed worst-case losses — strong risk profile

Annual Return

132.3%

Historical annualised return based on price data

Max Drawdown

-87.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.87

Less volatile than the market — more defensive

52W High

$71.50

63% below the year high

52W Low

$8.73

203% above the year low

Avg Volume

2,901,190

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.49

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

365.37

Heavy leverage — higher financial risk if revenues decline

Current Ratio

10.40

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

9.97

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,321.1%

Profit from core operations before interest and tax

Free Cash Flow

$-103,697,624

Negative — the business is spending more than it generates

Revenue (TTM)

$18M

Total revenue over the last 12 months

Net Income

$-208,868,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$94.29

Target Median

$35.07

Target Low

$13.90

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go